Wegovy and orlistat represent different approaches to weight management. Wegovy contains semaglutide and acts at GLP-1 receptors; orlistat acts locally in the digestive tract to reduce dietary fat absorption. Orlistat is marketed in the United States as prescription Xenical and nonprescription Alli, which means the question of access cannot be answered with one universal “prescription required” rule.
For an adult comparing options, the contrast extends beyond oral versus injectable formulations. Alli is an OTC 60-mg orlistat product with its own eligibility and Drug Facts instructions, while Xenical is the 120-mg prescription product. Wegovy spans a separate FDA-approved semaglutide brand family with oral and injectable formulations, each with its own labeling.
This comparison explains what the products do, their different access paths, the practical meaning of FDA label restrictions and the June 2026 FDA warning update for orlistat kidney injury. It does not present one medicine as a pharmacy substitute for the other or infer equivalent outcomes from unrelated trials.
Wegovy semaglutide acts through GLP-1 receptor pathways that affect appetite-related signaling and other metabolic functions. Orlistat inhibits gastrointestinal lipases, decreasing absorption of some fat consumed with food.
These mechanisms have different administration, diet-related instructions, interactions and adverse effect patterns. Being listed alongside each other in weight-loss searches does not make them pharmacologically or clinically interchangeable.
The right-hand column contains two different U.S. orlistat products: Alli 60 mg is available OTC under its Drug Facts conditions, while Xenical 120 mg requires a prescription. Wegovy is prescription-only in every approved form. Orlistat inhibits intestinal lipases; semaglutide acts at GLP-1 receptors. Neither route permits an equivalent-dose comparison.
In June 2026 FDA approved changes warning about rare kidney injury and stones for the OTC Alli label, harmonizing the renal-risk messaging across approved orlistat products. This does not revoke OTC status. A decision table must therefore distinguish advice to seek professional input, actual prescription requirements and ongoing monitoring without treating both brands of orlistat as one product.
| Comparison | Wegovy | Orlistat: Alli / Xenical |
|---|---|---|
| Active ingredient | Semaglutide | Orlistat |
| Main mechanism | GLP-1 receptor agonism | Gastrointestinal lipase inhibition |
| U.S. access | Prescription-only | Alli 60 mg OTC / Xenical 120 mg prescription |
| Route | Wegovy oral and injectable products | Oral capsules |
| Key safety frame | Product-specific GLP-1 boxed warning | Fat absorption effects; FDA kidney-risk update June 2026 |
| Purchase route | Valid prescription and licensed pharmacy | Follow exact OTC or prescription label |
Alli is FDA-approved over the counter as 60-mg orlistat capsules for eligible adults aged 18 and older under its Drug Facts conditions. Xenical is a prescription 120-mg orlistat product with its own obesity-management labeling.
A buyer who wants to learn how to obtain orlistat generally can use the orlistat buying guide. Product-specific paths are Alli OTC and Xenical prescription; combining them into one generic online prescription message would be incorrect.
Wegovy oral tablets, standard weekly injection and Wegovy HD are separate approved semaglutide products with distinct instructions and indicated populations. They require a licensed prescriber’s decision and legitimate pharmacy dispensing.
A retail OTC orlistat purchase does not demonstrate that Wegovy is necessary, safe or clinically appropriate. The two categories should be evaluated against their real labels and treatment goals.
On June 10, 2026, FDA announced updated warnings for OTC Alli 60-mg regarding rare kidney stones and kidney injury, bringing its warning language into alignment with other FDA-approved orlistat products. The update directs patients with a history of kidney disease or stones to speak with a health professional before use.
Readers should not assume OTC means risk-free. Follow current package instructions, consult a clinician when indicated and obtain urgent medical evaluation for concerning symptoms according to professional guidance.
Studies of GLP-1 weight management and older orlistat studies enroll different populations and have different durations, treatment support and outcome analyses. Contrasting headline averages as if both drugs were randomized together is misleading.
This page deliberately distinguishes the treatment categories, approvals and access routes rather than declaring a cross-trial efficacy winner or promising specific personal weight loss.
Orlistat can produce gastrointestinal fat-related effects and has relevant dietary, vitamin-absorption and medication considerations described in its labeling. Wegovy has its own boxed thyroid C-cell tumor warning and other GLP-1-related precautions.
People already taking medications or with chronic conditions should review all of them with a clinician or pharmacist. Combining either drug with other therapies without a plan is not justified by consumer comparisons.
For an Alli purchase, verify that the consumer meets the Drug Facts age and other label conditions and understands the fat-related gastrointestinal effects and potential interference with absorption of fat-soluble vitamins. Individuals with kidney disease or a history of kidney stones should follow the updated advice to consult a health professional before taking Alli.
For Xenical, confirm a prescription for the 120-mg product and its separate warnings. For Wegovy, confirm whether a tablet, ordinary pen or HD injection is prescribed. These are three regulatory paths; a cashier selling nonprescription Alli cannot authorize Xenical or Wegovy.
A pharmacy or retailer may correctly offer Alli over the counter while marketing it next to a prescription GLP-1 medicine. The buyer needs to understand this is a different mechanism and label, not a prescription-free form of Wegovy. The weight-management alternatives hub distinguishes these classes without inventing therapeutic equivalence.
Readers comparing U.S. regulatory status can also review the semaglutide FDA product directory. A legit OTC orlistat transaction does not override kidney-risk warnings, and a legitimate prescription Wegovy purchase still requires clinical authorization even when both options appear in one retail search.
Wegovy may be considered for its labeled indications under clinician care; no self-directed change to orlistat is justified by one medicine being sold without a prescription. Orlistat can cause treatment-relevant gastrointestinal effects and has specific vitamin-supplement and interaction considerations, which a pharmacist or clinician should review.
When discussing prescribed Xenical, check the precise product and other medicines rather than asking for any “orlistat strength.” A switch between Alli, Xenical and Wegovy is not a simple increase or decrease in drug milligrams. The alternative-treatment overview contextualizes the class choice.
A legitimate U.S. seller may offer Alli under OTC labeling, but an alleged nonprescription Wegovy or Xenical checkout is an important warning sign. Prescription products require a valid order and lawful pharmacy dispensing. For the separate transactions, use Alli OTC, Xenical prescription and Wegovy prescription.
For Alli, check that the package is correctly labeled 60 mg and that the current kidney warning is available. For Xenical or Wegovy, have the pharmacy match the exact prescription and labeled product; never assume a 120-mg orlistat capsule is an automatically authorized equivalent of two OTC capsules.
An OTC purchase of Alli often follows a consumer retail payment path, whereas prescription Xenical and Wegovy may involve separate insurance or self-pay programs. Check whether any health plan covers the specific product rather than extrapolating from a generic obesity-drug exclusion.
Normalize the supply period and include relevant ancillary costs; comparing the sticker price of an OTC package with an insured Wegovy copay is not a fair purchase comparison. The Wegovy price guide addresses pen/tablet offers without promoting dosage substitutions.
This is a mechanism, labeling and access comparison, not a prescription or weight-loss prediction. Readers should confirm the latest Drug Facts and prescribing information.
Commercial links, where present, may compensate this site but do not alter safety labeling, indication or pharmacy responsibilities.
No. Orlistat and semaglutide have different active ingredients and mechanisms.
Alli 60-mg orlistat is FDA-approved for OTC use in eligible adults when label directions are followed.
Yes. Xenical 120-mg orlistat is a prescription product.
No. U.S. Wegovy products require prescriptions.
FDA approved additional warnings about rare kidney stones and kidney injury.
No. Alli is 60 mg, whereas prescription Xenical is 120 mg.
No automatic interchangeability exists; they are different medicines.
No. Their adverse-effect and warning profiles differ by mechanism and product.
Separate trials do not provide a reliable personalized ranking; clinical assessment and exact evidence matter.